Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liming Wu

Showing results (321-330 of 343) with videos related to

Pageof 35
Sort By:
Nature|June 3, 2026
Queen cell architecture shapes honey bee queen developmentYu Fang, Beibei Ma, Xiaolu Jin, et al.
Aesthetic Surgery Journal|February 15, 2026
Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese AdultsYan Wu, Xiao Long, Nanze Yu, et al.
Dermatology and Therapy|February 11, 2026
Real-World Characteristics, Treatment Patterns, and Outcomes in Adult Patients Receiving Abrocitinib for Atopic Dermatitis in China: Interim Analysis from the AHEAD RegistryLi Zhang, Naihui Zhou, Zhouwei Wu, et al.
Clinical Immunology (Orlando, Fla.)|March 31, 2012
CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndromeXiying Fan, Bhaskar Upadhyaya, Liming Wu, et al.
The British Journal of Dermatology|September 19, 2025
Efficacy and Safety of Pumecitinib Gel for Treating Mild-to-moderate Atopic Dermatitis: a Multicentre, Randomised, Double-blind, Parallel, Placebo-controlled Phase IIb Clinical TrialLi Zhang, Mingyue Wang, Litao Zhang, et al.
Journal of the American Academy of Dermatology|September 21, 2025
Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trialCheng Zhou, Chunjun Yang, Weixin Fan, et al.
Allergy|October 25, 2024
Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trialYan Zhao, Litao Zhang, Liming Wu, et al.
Chinese Medical Journal|July 23, 2023
Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trialYan Zhao, Jianzhong Zhang, Bin Yang, et al.
Advances in Therapy|January 27, 2026
Efficacy and Safety of Switching to Picankibart from Non-interleukin-23 Subunit p19 Inhibitors in Patients with Plaque Psoriasis: A Multicenter, Open-Label, Phase 2 TrialQing Yang, Bin Yang, Heng Gu, et al.
Journal of the American Academy of Dermatology|April 10, 2025
Efficacy and safety of SYSA1902 versus reference ustekinumab in moderate-to-severe plaque psoriasis: A multicenter, randomized, phase III studyLixin Xia, Guoying Miao, Xiumin Yang, et al.
Pageof 35

Showing results (321-330 of 343) with videos related to

Sort By:
Pageof 35
Nature|June 3, 2026
Queen cell architecture shapes honey bee queen developmentYu Fang, Beibei Ma, Xiaolu Jin, et al.
Aesthetic Surgery Journal|February 15, 2026
Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese AdultsYan Wu, Xiao Long, Nanze Yu, et al.
Dermatology and Therapy|February 11, 2026
Real-World Characteristics, Treatment Patterns, and Outcomes in Adult Patients Receiving Abrocitinib for Atopic Dermatitis in China: Interim Analysis from the AHEAD RegistryLi Zhang, Naihui Zhou, Zhouwei Wu, et al.
Clinical Immunology (Orlando, Fla.)|March 31, 2012
CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndromeXiying Fan, Bhaskar Upadhyaya, Liming Wu, et al.
The British Journal of Dermatology|September 19, 2025
Efficacy and Safety of Pumecitinib Gel for Treating Mild-to-moderate Atopic Dermatitis: a Multicentre, Randomised, Double-blind, Parallel, Placebo-controlled Phase IIb Clinical TrialLi Zhang, Mingyue Wang, Litao Zhang, et al.
Journal of the American Academy of Dermatology|September 21, 2025
Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trialCheng Zhou, Chunjun Yang, Weixin Fan, et al.
Allergy|October 25, 2024
Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trialYan Zhao, Litao Zhang, Liming Wu, et al.
Chinese Medical Journal|July 23, 2023
Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trialYan Zhao, Jianzhong Zhang, Bin Yang, et al.
Advances in Therapy|January 27, 2026
Efficacy and Safety of Switching to Picankibart from Non-interleukin-23 Subunit p19 Inhibitors in Patients with Plaque Psoriasis: A Multicenter, Open-Label, Phase 2 TrialQing Yang, Bin Yang, Heng Gu, et al.
Journal of the American Academy of Dermatology|April 10, 2025
Efficacy and safety of SYSA1902 versus reference ustekinumab in moderate-to-severe plaque psoriasis: A multicenter, randomized, phase III studyLixin Xia, Guoying Miao, Xiumin Yang, et al.
Pageof 35